Moderna and Merck have announced that late-stage trials of a personalised mRNA cancer vaccine for the treatment of melanoma have yielded positive results. The companies stated that the treatment reduced the risk of melanoma recurrence or spread when used in conjunction with Merck’s immunotherapy drug Keytruda. Notably, Keytruda is already widely used to treat melanoma and several other cancers. This…
Tag: Melanoma
-
Lower-Dose Immunotherapy Trials Expand Treatment Options
Ground-breaking new research suggests that dramatically lower doses or shorter courses of revolutionary immunotherapy drugs could be highly effective. This finding may eventually pave the way for wider global access to life-saving cancer treatments. Lower-dose immunotherapy trials are showing promising potential. Drugs like Merck & Co’s Keytruda and Bristol Myers Squibb Co’s Opdivo have transformed oncology. They boost survival rates…
-
SA Scientists Pioneer Nanotech Therapy for Lethal Melanoma
In a significant medical breakthrough, scientists from the University of the Witwatersrand (Wits) have developed a novel therapy for melanoma, the most dangerous form of skin cancer. The innovative treatment combines advanced nanotechnology with a natural compound found in turmeric. This combination provides a powerful, targeted attack directly to cancer cells. The research by Wits University’s Advanced Drug Delivery Platform…